Todos Med Ltd (TOMDF)

[redspeed]

As a consequence, NLC Pharma has assigned ownership of all relevant intellectual property to majority-owned joint venture 3CL Pharma Ltd. The assignment includes the patent applications for dual mechanism (3CL protease inhibitor and CCR5 antagonist) Phase 2 therapeutic drug candidate Tollovir™, commercial-stage 3CL protease inhibitor immune support supplement Tollovid™, and 3CL protease biomarker test TolloTest™ for SARS-CoV-2 infectivity monitoring and PASC/Long COVID viral persistence assessment (“The IP”).

CCR5 antagonist getting mentioned again.

Todos is targeting a crowdfunding launch ahead of October 6th, 2022 in alignment with the FDA’s Adcom meeting for Veru, Inc.’s sabizabulin which is another COVID-19 drug seeking approval in the hospitalized setting.

Now we know the crowd funding will start within the next 4 weeks so people don't have to ask GC on twitter everyday.